Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
632.90
+12.76 (2.06%)
At close: Jun 26, 2026, 4:00 PM EDT
631.38
-1.52 (-0.24%)
After-hours: Jun 26, 2026, 7:57 PM EDT
Regeneron Pharmaceuticals Stock Forecast
Stock Price Forecast
The 25 analysts with 12-month price forecasts for Regeneron Pharmaceuticals stock have an average target of 831.08, with a low estimate of 641 and a high estimate of 995. The average target predicts an increase of 31.31% from the current stock price of 632.90.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Regeneron Pharmaceuticals stock from 29 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 17 | 18 | 18 | 16 | 16 |
| Buy | 2 | 2 | 4 | 4 | 5 | 5 |
| Hold | 8 | 8 | 7 | 7 | 8 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 27 | 27 | 29 | 29 | 29 | 29 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $788 | Hold | Maintains | $788 | +24.51% | Jun 25, 2026 |
| Citi | Citi | Hold Maintains $700 | Hold | Maintains | $700 | +10.60% | Jun 22, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $855 | Buy | Maintains | $855 | +35.09% | Jun 2, 2026 |
| BMO Capital | BMO Capital | Buy Maintains $730 | Buy | Maintains | $730 | +15.34% | May 21, 2026 |
| Scotiabank | Scotiabank | Hold Maintains $770 | Hold | Maintains | $770 | +21.66% | May 19, 2026 |
Financial Forecast
Revenue This Year
15.88B
from 14.34B
Increased by 10.72%
Revenue Next Year
17.55B
from 15.88B
Increased by 10.53%
EPS This Year
46.25
from 44.31
Increased by 4.37%
EPS Next Year
53.77
from 46.25
Increased by 16.27%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 17.2B | 19.1B | |
| Avg | 15.9B | 17.6B | |
| Low | 14.6B | 16.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 19.8% | 20.2% | |
| Avg | 10.7% | 10.5% | |
| Low | 2.0% | 2.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | 46.25 | 53.77 | |
| Low | - | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | 4.4% | 16.3% | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.